Graves' OphthalmopathyNCT00174057
The Role of TSH Receptor, PPAR-r, IGF-1R, IGF and Cytokines in Different Stages of Graves'Ophthalmopathy
An observational study of Graves' Ophthalmopathy, run by National Taiwan University Hospital at 1 site in Taiwan.
Trial summary
The exact mechanism of the pathogenesis of Graves' ophthalmopathy is still unknown. Histopathologically, extraocular muscle inflammation and orbital fat inflammation are two prominent changes. Read more about this study
- Who is it for?
- Ages 20 years and older
- Conditions the study is for
- Graves' Ophthalmopathy
- How many people
- 50 participants
- Where
- 1 siteTaiwan
- Study dates
- Aug 2005to Jul 2006
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 20 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
None listed.
Who cannot join
- -
Trial locations and contacts
1 site in 1 country.
Taiwan1 site, 1 recruiting
- Recruiting
Shu Lang Liao
Taipei
Shu Lang Liao, MD, 886-2-23123456 ext. 5729, lang89@ha.mc.ntu.edu.tw
Luke L-K Lin, PhD
About this study
The exact mechanism of the pathogenesis of Graves' ophthalmopathy is still unknown. Histopathologically, extraocular muscle inflammation and orbital fat inflammation are two prominent changes. In the past year, we had investigated the morphological features of the Müller muscle in patients with thyroid lid retraction using the special stain and immunohistochemistry. In our findings, the smooth muscle cells, in the diseased group, were replaced by variable adipose and fibrosis tissues.
In recent years, TSHR, has been verified to express in orbital connective tissue and extra-ocular muscle. From functional studies and an increase in adipogenesis in cultured fibroblasts with expression of TSHR protein, the role not only the target but effector cells in orbital fibroblasts were validated. Quantitative RT-PCR may help to differentiate whether a less extent of expression at the end stage or low protein amount to be detected.
Read more
In recent years, the diverse phenotypes of orbital fibroblasts, with regard to expression of Thy-1 protein or not, had been reported from several studies, the investigators believed heterogeneity in orbital fibroblast may determine the clinical presentation of Graves'ophthalmopathy. We also are curious to know if the phenotypic heterogeneity of the fibroblasts in the ocular adnexal and orbital tissues correlates to distinct morphological features of adipogenesis and fibrosis.
Moreover, increased CD40 expression in skin fibroblasts were noted from patients with systemic sclerosis. Expression of IGF-I and IGF-IR seemed to be up-regulated in processes of several fibrotic diseases. A nuclear transcription factor, PPAR-γ, has been verified to have a close relationship with adipogenesis. We hypothesize that some immunological processes involve the ocular adnexal and orbital tissues, which result in various ophthalmological manifestations.
The purpose of this study is to investigate the different stage of the ocular adnexal and orbital tissues to identify the pathogenesis of Graves' ophthalmopathy by frozen sections with Immunohistochemistry, mRNA expression of TSH receptor, PPAR-γ, IGF-1R, and IGF-1 and different cytokines using quantitative RT-PCR and flow cytometry at the acute and stable stage in GO.
Read the detailed description
The exact mechanism of the pathogenesis of Graves' ophthalmopathy (GO) is still unknown. Histopathologically, extraocular muscle inflammation due to lymphoid infiltration, edema and interstitial fibrosis, and increased glycosaminoglycan deposition and orbital fat inflammation are two prominent changes. There are various manifestations including ocular adnexal tissues inflammation, proptosis, lid retraction, extraocular movement limitation and compressive optic neuropathy. In the past year, we had investigated the morphological features of the Müller muscle in patients with thyroid lid retraction using the special stain and immunohistochemistry in formalin-fixed paraffin-embbeded (FFPE) sections. In our findings, the smooth muscle cells, in the diseased group, were replaced by variable adipose and fibrosis tissues. Two distinct features in the disease group seem to be notable for further investigation.
In recent years, TSHR, a putative autoantigen, has been verified to express in orbital connective tissue and extra-ocular muscle. In addition, they were further demonstrated to express on the surface of cultured orbital fibroblasts and orbital adipose tissue, in patients with GO in several laboratories. From functional studies and an increase in adipogenesis in cultured fibroblasts with expression of TSHR protein, the role not only the target but effector cells in orbital fibroblasts were validated7. We used immunohistochemistry to verify the existence of TSHR on the fibroblasts within the Müller muscle, and the positive staining is manifested in only18 % of patients. It may due to a less extent of expression at the end stage. We are very curious to know if there any difference on the expression of TSHR between orbital specimens from patients with acute and those with stable stage. Quantitative RT-PCR may help to differentiate whether a less extent of expression at the end stage or low protein amount to be detected.
In recent years, the diverse phenotypes of orbital fibroblasts, with regard to expression of Thy-1 protein or not, had been reported from several studies, the investigators believed heterogeneity in orbital fibroblast may determine the clinical presentation of Graves' ophthalmopathy. We also are curious to know if the phenotypic heterogeneity of the fibroblasts in the ocular adnexal and orbital tissues correlates to distinct morphological features of adipogenesis and fibrosis. In addition, systemic or local pro-inflammatory cytokines may contribute to turn on and turn off the expression of different roles of the fibroblasts.
Moreover, increased CD40 expression in skin fibroblasts were noted from patients with systemic sclerosis. Expression of IGF-I and IGF-IR seemed to be up-regulated in processes of several fibrotic diseases. A nuclear transcription factor, PPAR-γ, has been verified to have a close relationship with adipogenesis. In our previous study, the smooth muscle cells, in the diseased Mullers' muscle, were replaced by variable adipose and fibrosis tissues. The increased adipose and fibrosis tissue ex vivo of the Müller' muscle may result from over-action of some biochemical markers in the fibroblasts infiltrating around muscle cells. We hypothesize that some immunological processes involve the ocular adnexal and orbital tissues, which result in various ophthalmological manifestations.
The purpose of this study is to investigate the different stage ( acute or stable stage) of the ocular adnexal and orbital tissues ( including orbital fat, extraocular muscles, orbicularis muscles and eyelid fat) to identify and validate the pathogenesis of Graves ophthalmopathy by frozen sections of the ocular adnexal and orbital tissues with Immunohistochemistry (IHA) (Thy-1 and PPARγ), mRNA expression of TSH receptor, PPAR-γ, IGF-1R, and IGF-1 and different cytokines (IL-1β, IL-4, IL-6, IL-8) using quantitative RT-PCR and flow cytometry at the acute and stable stage in GO.
- Conditions
- Graves' Ophthalmopathy
- Keywords
- Graves' ophthalmopathy, real time PCR, cytokines, Tsh receptor
- Medical subject headings
- Graves Ophthalmopathy
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted15 Sep 2005 (estimated)
- Study startAug 2005
- Study completionJul 2006
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Graves' OphthalmopathyStudies of the same condition, open and under way.
- More trials run by National Taiwan University HospitalThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case-control
- Time perspective
- Other
- Enrolment
- 50 participants
Sponsor and investigators
- Lead sponsor
- National Taiwan University Hospital
- Sponsor type
- University, hospital or other
- Investigators
- Shu Lang Liao, MD, Study director, National Taiwan University Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00174057
- Sponsor's protocol ID
- 9461700644
- Status last verified
- Jun 2005
- First submitted
- 13 Sep 2005
- Last updated
- 15 Sep 2005
- Results posted
- No
Study at a glance
From the registry record, last updated by the sponsor on 15 Sep 2005. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Role of TSH Receptor, PPAR-r, IGF-1R, IGF and Cytokines in Different Stages of Graves'Ophthalmopathy
- ClinicalTrials.gov ID
- NCT00174057
- Acronym / sponsor ID
- 9461700644
- Conditions
- Graves' Ophthalmopathy
- Keywords
- Graves' ophthalmopathy, real time PCR, cytokines, Tsh receptor
- Study type
- Observational
- Recruitment status
- Unknown status
- Enrolment
- 50 participants
- Lead sponsor
- National Taiwan University HospitalUniversity, hospital or other
- Study start
- Aug 2005
- Study completion
- Jul 2006
- First posted
- 15 Sep 2005 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The exact mechanism of the pathogenesis of Graves' ophthalmopathy is still unknown. Histopathologically, extraocular muscle inflammation and orbital fat inflammation are two prominent changes. In the past year, we had investigated the morphological features of the Müller muscle in patients with thyroid lid retraction using the special stain and immunohistochemistry. In our findings, the smooth muscle cells, in the diseased group, were replaced by variable adipose and fibrosis tissues.
In recent years, TSHR, has been verified to express in orbital connective tissue and extra-ocular muscle. From functional studies and an increase in adipogenesis in cultured fibroblasts with expression of TSHR protein, the role not only the target but effector cells in orbital fibroblasts were validated. Quantitative RT-PCR may help to differentiate whether a less extent of expression at the end stage or low protein amount to be detected.
In recent years, the diverse phenotypes of orbital fibroblasts, with regard to expression of Thy-1 protein or not, had been reported from several studies, the investigators believed heterogeneity in orbital fibroblast may determine the clinical presentation of Graves'ophthalmopathy. We also are curious to know if the phenotypic heterogeneity of the fibroblasts in the ocular adnexal and orbital tissues correlates to distinct morphological features of adipogenesis and fibrosis.
Moreover, increased CD40 expression in skin fibroblasts were noted from patients with systemic sclerosis. Expression of IGF-I and IGF-IR seemed to be up-regulated in processes of several fibrotic diseases. A nuclear transcription factor, PPAR-γ, has been verified to have a close relationship with adipogenesis. We hypothesize that some immunological processes involve the ocular adnexal and orbital tissues, which result in various ophthalmological manifestations.
The purpose of this study is to investigate the different stage of the ocular adnexal and orbital tissues to identify the pathogenesis of Graves' ophthalmopathy by frozen sections with Immunohistochemistry, mRNA expression of TSH receptor, PPAR-γ, IGF-1R, and IGF-1 and different cytokines using quantitative RT-PCR and flow cytometry at the acute and stable stage in GO.
Detailed description
The exact mechanism of the pathogenesis of Graves' ophthalmopathy (GO) is still unknown. Histopathologically, extraocular muscle inflammation due to lymphoid infiltration, edema and interstitial fibrosis, and increased glycosaminoglycan deposition and orbital fat inflammation are two prominent changes. There are various manifestations including ocular adnexal tissues inflammation, proptosis, lid retraction, extraocular movement limitation and compressive optic neuropathy. In the past year, we had investigated the morphological features of the Müller muscle in patients with thyroid lid retraction using the special stain and immunohistochemistry in formalin-fixed paraffin-embbeded (FFPE) sections. In our findings, the smooth muscle cells, in the diseased group, were replaced by variable adipose and fibrosis tissues. Two distinct features in the disease group seem to be notable for further investigation.
In recent years, TSHR, a putative autoantigen, has been verified to express in orbital connective tissue and extra-ocular muscle. In addition, they were further demonstrated to express on the surface of cultured orbital fibroblasts and orbital adipose tissue, in patients with GO in several laboratories. From functional studies and an increase in adipogenesis in cultured fibroblasts with expression of TSHR protein, the role not only the target but effector cells in orbital fibroblasts were validated7. We used immunohistochemistry to verify the existence of TSHR on the fibroblasts within the Müller muscle, and the positive staining is manifested in only18 % of patients. It may due to a less extent of expression at the end stage. We are very curious to know if there any difference on the expression of TSHR between orbital specimens from patients with acute and those with stable stage. Quantitative RT-PCR may help to differentiate whether a less extent of expression at the end stage or low protein amount to be detected.
In recent years, the diverse phenotypes of orbital fibroblasts, with regard to expression of Thy-1 protein or not, had been reported from several studies, the investigators believed heterogeneity in orbital fibroblast may determine the clinical presentation of Graves' ophthalmopathy. We also are curious to know if the phenotypic heterogeneity of the fibroblasts in the ocular adnexal and orbital tissues correlates to distinct morphological features of adipogenesis and fibrosis. In addition, systemic or local pro-inflammatory cytokines may contribute to turn on and turn off the expression of different roles of the fibroblasts.
Moreover, increased CD40 expression in skin fibroblasts were noted from patients with systemic sclerosis. Expression of IGF-I and IGF-IR seemed to be up-regulated in processes of several fibrotic diseases. A nuclear transcription factor, PPAR-γ, has been verified to have a close relationship with adipogenesis. In our previous study, the smooth muscle cells, in the diseased Mullers' muscle, were replaced by variable adipose and fibrosis tissues. The increased adipose and fibrosis tissue ex vivo of the Müller' muscle may result from over-action of some biochemical markers in the fibroblasts infiltrating around muscle cells. We hypothesize that some immunological processes involve the ocular adnexal and orbital tissues, which result in various ophthalmological manifestations.
The purpose of this study is to investigate the different stage ( acute or stable stage) of the ocular adnexal and orbital tissues ( including orbital fat, extraocular muscles, orbicularis muscles and eyelid fat) to identify and validate the pathogenesis of Graves ophthalmopathy by frozen sections of the ocular adnexal and orbital tissues with Immunohistochemistry (IHA) (Thy-1 and PPARγ), mRNA expression of TSH receptor, PPAR-γ, IGF-1R, and IGF-1 and different cytokines (IL-1β, IL-4, IL-6, IL-8) using quantitative RT-PCR and flow cytometry at the acute and stable stage in GO.
Study design
- Observational model
- Case-control
- Time perspective
- Other
Who may qualify
- Ages
- 20 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (0 listed)
Key exclusion criteria (1 listed)
- -
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Not reported in the source record.
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 15 Sep 2005.
Related trials for Graves' Ophthalmopathy
Not yet recruiting
Impact of Restrictive Diets on Inflammation and Quality of Life in Autoimmune Thyroiditis
Thyroid Autoimmune Disease, Hashimoto's Thyroiditis
RecruitingPhase 3
A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC PFS in Adult Participants With Graves' Disease
Graves' Disease, Graves Disease
RecruitingPhase 3
A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC PFS in Adult Participants With Graves' Disease.
Graves Disease
Active, not recruitingPhase 4
Hydroxychloroquine in Mild Graves' Orbitopathy
Graves Ophthalmopathy
RecruitingPhase 2
A Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Participants With Graves' Disease
Graves' Disease
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Shu Lang Liao, MD study director
National Taiwan University Hospital
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Graves' Ophthalmopathy, run by National Taiwan University Hospital at 1 site in Taiwan.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 0 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 15 Sep 2005. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Taiwan. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Each site lists its own contact: choose the nearest one under Trial locations. AzTrials does not enrol participants or take referrals.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 Sep 2005.